Personalized Serial Circulating Tumor DNA Analysis in High-Risk Early Stage Breast Cancer Patients

July 28, 2021

Analysis of circulating tumor DNA (ctDNA) offers a minimally invasive approach for monitoring treatment response and resistance to treatment in patients with breast cancer.

Download PDF

Personalized Serial Circulating Tumor DNA Analysis in High-Risk Early Stage Breast Cancer Patients

Using ctDNA to help inform the management of patients with low-risk colorectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

Personalized tumor-informed circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients rece

Impact of Number of Variants in WES-based MRD Assays

How ctDNA can transform interventional trial design for GI cancers

US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detec

Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer

Utility of ctDNA in assessment of treatment response in patients with Recurrent/Metastatic Endometrial Cancer and Recurrent/Platinum-Resista

Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring in patients with advanced or recurrent uterine

PARPi response monitoring using personalized circulating tumor DNA testing in patients with ovarian cancer

Treatment Monitoring Utilizing ctDNA-based Molecular Residual Disease Detection in Early Stage Uterine Cancer

Utility of ctDNA as an Early Predictive Biomarker of Response to RT/CRT in Gynecologic Malignancies

Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian

SSO Industry Spotlight 2024

Compassionate Care Application - Spanish

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Utility of circulating tumor DNA (ctDNA) for the detection of minimal residual disease (MRD) after curative-intent therapy for patients with

The role of pre-operative ctDNA in resectable intrahepatic cholangiocarcinoma